I fled the UK for sunny Dubai – life back home is miserable & no-one has any cash, I was wasting my life away there
A YOUNG woman has revealed how her health improved after she moved from the UK to Dubai – saying life at home was 'making her sick'.
Ela Reeves was struggling with a series of health conditions prior to the move, including
5
Ela, who hails from Essex, was struggling with a series of health conditions prior to the move
Credit: Jam Press/@elareevesx
5
The woman says her quality of life improved immediately – and she feels healthier than ever
Credit: Jam Press/@elareevesx
5
She describes the UK as 'such a depressing place to live'
Credit: Jam Press/@elareevesx
With her body 'crying out for change', she decided to try life in sunnier climes – and jetted off to
Working remotely there for her job at a luxury travel company, Ela says her quality of life improved immediately – and she feels healthier than ever.
'
'The UK was quite literally making me sick.
read more on travel
'I thought that I had all of these
'I just didn't feel my best self despite being somebody who is always health conscious, always eating the right things, going to the gym, and
'It was so draining to the point that I was focusing on my health so much and wasn't really getting the results that I should have been.
'I was like 'What the hell is wrong with me?''
Most read in Fabulous
Prior to moving to Dubai, Ela says she had 'severe' acne, struggling with bloating due to high cortisol levels, and says the lifestyle and weather in the UK limited her.
Since leaving, she has noticed a huge difference in her health and has lost weight.
I'm a Dubai millionaire's wife - yes my life is glamorous but there's a big problem with being married to a rich man
Ela said: 'I'm [now] doing 20,000 steps a day, and my
'I have so much energy – I never thought I would have this amount of energy.
'Despite getting eight hours of sleep and trying to stay off of my phone before I go to bed and stuff, I just always felt drained and tired.
'I just kind of gave up on that for a bit and thought that was just me as a person – but not here.
How easy is it to move abroad?
Brexit means British citizens now have to apply for visas to move to countries within the EU. While some countries residency restrictions are easier than others, here's what you need to do at home before moving:
Notify HMRC about your upcoming move.
Let your local authority know and provide a forwarding address.
Contact your mortgage and utility providers and bank before leaving.
If you have paid enough UK national insurance contributions, you can qualify for a state pension abroad - contact the
You can sign up to the Royal Mail's
If you have outstanding student loans, contact the
If you have children, give due notice to childcares and schools.
'I can work till late at night, I can get up early in the morning and I feel fresh.
'Even if I get less sleep now, I've still got the energy because I'm constantly outside getting fresh air and sunlight.'
Ela describes the UK as 'such
She cites the weather as a 'huge factor', saying she now walks a lot more, and spends her afternoons at
Ela said: 'I'm not wasting hours indoors anymore
'There's always something to do here, and that shift alone has made me feel more energised and productive.
5
Ela has visited home to sort out visa issues and says her health issues have immediately resurfaced as a result.
Credit: Jam Press/@elareevesx
5
She now works remotely for her job at a luxury travel company
Credit: Jam Press/@elareevesx
'Life feels full again, not wasted.
'In the UK, the days felt so repetitive, scrolling on my phone and watching TV.
'And with
'I've actually loved the experience of
'My family has also come to visit, and thankfully we all have the flexibility to travel and see each other when we want to.'
Ela has visited home to sort out
She said: 'I'm back in the UK temporarily and already my acne has flared up again, and I'm feeling constantly fatigued.
'It honestly just confirms what I suspected: being in the UK really does impact my health.
'In my opinion, the UK isn't a happy place anymore.
'So many people are struggling with their health, finances, and, let's be honest, the weather.
'There are incredible opportunities for young people abroad – go and find them!'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTÉ News
5 hours ago
- RTÉ News
Bitter pill: EU exploits Trump anti-science climate to forge deal on medicines
The EU's sweeping new rules on the regulation of medicines has been one of the most bitterly contested pieces of legislation in recent times, with fierce lobbying by the pharma sector - particularly in Ireland - and member states divided on which to prioritise: cheaper medicines for patients, or a regulatory environment that supports indigenous European manufacturers in the face of US dominance. After two years of deadlock, 26 member states have agreed on a compromise proposal, with only Malta - which has its own small-market medicines challenge - abstaining. Ironically, it was the Trump administration's hostility to science and medicine regulators that convinced EU member states that the moment to finally agree on a new set of rules was at hand. "In the US you have a chaotic situation," says one source familiar with negotiations, "between [Health Secretary] Robert Kennedy Jr, who doesn't believe in science or vaccines, and the Trump administration, which has sacked three and a half thousand people from the Food and Drugs Administration. "There was a sense in Europe that we should try to get this proposal settled so that we have a stable system in Europe when there's instability elsewhere." The legislation will now go to the European Parliament, where negotiations between MEPs, the member states and the European Commission, begin on 17 June. There are hopes that the entire package could be adopted by the end of the year. The European Commission first proposed overhauling the EU's medicines regime in April 2023, as Europe was emerging from the Covid pandemic. The EU was reeling from the strain the emergency put on health systems and on the availability of certain kinds of medicines, with a deepening awareness that Europe was overly dependent on China and India for drugs such as antibiotics. At the same time, digitalisation and the availability of clinical data were opening up new possibilities in how medicines are developed and used. Despite that, innovative therapies were not reaching patients across Europe at the same speed while in some member states patients did not have access to medicines they needed due to shortages. The instinct to reduce health spending further has been given fresh impetus by the expected surge in EU defence expenditure following Russia's invasion of Ukraine. Overall, the pharma package sought to boost the competitiveness of the sector, reduce the administrative burden - and the over-reliance on India and China - and to tackle the environmental impact of drug manufacture and use. The central, most divisive issue was around the protection that big European pharma countries would have in holding on to clinical data before generic manufacturers - who could produce cheaper drugs - could access it. It became a straightforward contest between the competing interests of big pharma, which argued that companies needed the protection in order to invest more in life-saving domestic European research and innovation, and those countries which were more interested in lowering the cost of medicines and making those medicines more accessible to patients. The legislation was always going to face a stormy passage. "The difficulty was that the countries that didn't have pharmaceutical industries were very much opposing the regulatory data protection (RDP) element because all they were interested in was making medicines available to citizens," says Fianna Fáil MEP Billy Kelleher, a substitute member of the European Parliament health committee. "Eastern European countries like Poland, Romania, Bulgaria and others would have been very, very reluctant to support the strong protection of regulatory data, while it was the old West, countries like Ireland, Belgium, Italy, Germany and the Netherlands that have big manufacturing and pharma centres, a lot of research and development, who were pushing for it." The new rules would attempt to reconcile the issue of regulatory data protection, which theoretically encourages pharmaceutical companies to invest more in life-saving medicines, with the need to make drugs more affordable. Under existing EU rules, pharma companies were entitled to keep clinical data for eight years - the so-called regulatory data protection (RDP) before they were obliged to make it accessible. After the eight years was up, generic producers could file an application to use the data, at which point the patent holder enjoyed a further two - and sometimes three - extra years of protection. Under the commission's 2023 proposal, there would be a two-year reduction in the baseline RDP to six years, with an extra two years of protection. However, pharma companies could claw back a further two years of protection - extending RDP to ten years. The ten-year protection period would be available if the patent holder won approval for significant new innovations (one extra year of protection), if the product addressed an "unmet medical need", ie, where there was product authorised in the EU for a particular disease, or where the disease was associated with a high death-rate (such a situation would merit an extra six months of market protection), or if the manufacturer conducted clinical trials or extended access to all member states (another six months). Essentially, the commission was attempting to balance the need to reward medicines that meet the greatest clinical need, while speeding up access to generic producers who will make drugs that are cheaper. However, the new rules were facing hostility from traditional pharma manufacturing countries such as Germany, France, Denmark and the Netherlands, who argued that a shorter clinical data protection period would stymie research. The Irish Times reported on a full scale lobbying effort by industry, including a claim in a letter to Tánaiste Simon Harris by the Irish Pharmaceutical Healthcare Association (IPHA) that the proposal could lead to a 22% drop in new medicines being developed over the coming decade. It is understood there were tensions between the IDA and Enterprise Ireland, who shared the concerns of industry, and the Department of Health, which was more concerned with lowering the cost of medicines and making them more accessible. A number of sources have said that while member states with important pharma sectors went public two years ago, when the commission first proposed reducing clinical data protection from eight years to six, in demanding the status quo of eight years, Ireland remained on the fence, and did so right up until a key meeting of EU ambassadors on 21 May. On that date, Ireland joined a blocking majority of ten countries - including Belgium, Denmark, the Netherlands and Germany - to oppose the latest Polish proposal that would have essentially increased the RDP by one year to seven, but short of eight. As a result of that blocking minority, the Poles came back with another compromise text, which is - to all intents and purposes - a return to eight years, with various caveats and conditions designed to make medicines cheaper and more accessible (one part of the text aims to ensure that medicinal products are available in all member states and provides for regulatory action if the marketing authorisation holder does not comply). Officials say the text provides more reassurance for generic producers, and will cut timelines for authorised medicines to get to market. There are other measures, including making it easier to have multi-country and multilingual medicine packs, which should reduce production costs and make it easier to move medicines around Europe. At yesterday morning's meeting of EU ambassadors, the new text received overwhelming support. The IPHA are understood to be broadly satisfied with the compromise. In a statement, the organisation said it "believes the [member states] position represents a more balanced approach than had originally been proposed by the Commission. "As the legislative process enters the final phase, EU decision makers must continue to find solutions that will keep Europe competitive through a predictable and globally competitive environment for research, development and manufacturing, while ensuring fairer access to innovative medicines for patients across the EU." Support is not uniform. The chief executive of the Confederation of Danish Industry Lars Sandahl Sørensen accused member states of triggering a potential flight of European industry to Trump's America. "We are de facto making the EU's pharmaceutical industry less competitive and thus European society vulnerable," he said. The European pharma lobby group EFPIA described yesterday's position by member states as "a missed opportunity to position Europe's life sciences sector at the forefront of global competition". In a statement, EFPIA said: "The choice to reduce intellectual property protections for pharmaceutical companies makes Europe less attractive, discouraging investment and jeopardising the development of innovative treatments in Europe without addressing the underlying barriers and delays to patient access." There is some scepticism over the industry's seeming exploitation of Donald Trump's persistence in threatening tariffs on European pharmaceutical exports and reshoring manufacturing to the US. In April the industry wrote to commission president Ursula von der Leyen, suggesting that €50.6 billion in capital investment and €52.6bn in research and development expenditure were at risk if the EU continued to over-regulate the pharma sector. "Unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US," EFPIA warned. Officials suggest the upcoming Critical Medicines Act (CMA) will further boost access to cheaper medicines. Drugs such as those for diabetes or HRT have been susceptible to disruption and shortages in recent years because they are often generic and produced outside the EU. The CMA will aim to encourage more manufacturing of such drugs in Europe. The action now moves to the European Parliament, where so-called trilogues - three way negotiations between member states, the Commission and MEPs - will further shape the legislation. Last year the parliament adopted its own position, calling for an RDP of seven and a half years with the possibility of some extensions. The parliament has since moved to the right, following last year's elections, so it remains to be seen if further battles are expected.
The Irish Sun
15 hours ago
- The Irish Sun
Footballer, 35, dies after suffering cardiac arrest on pitch just hours after sharing deep message about ‘soul and life'
A FOOTBALLER has died after collapsing on the pitch following a reported cardiac arrest - having shared a poignant message just hours earlier. Enzo Pittau, 35, the dad of a new baby girl, lost his footing several times before his collapse 41 minutes into a cup game. 2 Argentinian football is in shock over Enzo Pittau's death Credit: Jam Press 2 Pittau had shared what now reads as a poignant message Credit: Twitter Pittau was playing for Don Orione away to Club Union in Argentina's Chaco federation tournament. Witnesses say there was " and crying" as those nearby saw his fall and realised how serious the situation was. Media outlet The Chaco League star had played for numerous clubs in the area, also enjoying spells in Italy, Switzerland and Spain. READ MORE IN FOOTBALL Football in the area, north of Argentina capital Buenos Aires, is in mourning and shock following his death. A few hours before the match Pittau posted a touching message and photo on social media. He wrote: "The faith and God in between. Today we play with soul and life." Alongside those words was a picture of his football top and shin guards - which had photos of his new daughter. Most read in Sport Pittau's club said: "With deep pain, we communicate the death of Enzo Pittau. We are shocked and affected by this loss. "We appreciate your solidarity and understanding in this difficult time for our club and Enzo Pittau's family." We were all in shock, the players and us in the stands. The match was stopped for a while and then suspended. Witness A witness told Diario Chaco via "I can still see it, and it's very painful. "Everything turned into chaos. People were running, screaming, crying, and yelling for help. "From the stands, we didn't really know what had happened, but it was awful." Another witness said: "I have this image of Pittau falling alone. I can't get it out of my head. "We're dismayed by what happened. "It hurts quite a bit. We were all in shock, the players and us in the stands. The match was stopped for a while and then suspended." Local media say Pittau had returned to Chaco to be near his family after his grandfather had health problems. Sunday's tragic match was the return leg in the second phase of the Argentinian Federativo tournament's second phase.
The Irish Sun
15 hours ago
- The Irish Sun
Popular beauty influencer Guava Shuishui who was known for eating make-up products dies aged 24 after ‘sudden illness'
TAIWANESE beauty influencer Guava Shuishui has died at the age of 24 as a result of a "sudden illness". The content creator, known to her fans as Guava Beauty, often tasted products as she tested them. 3 Influencer Guava Shuishui has died suddenly aged 24 Credit: Jam Press 3 A post shared to her social media account revealed she died from a 'sudden illness' Credit: Jam Press 3 Guava was known for tasting products as she tested them Credit: Jam Press According to a social media post shared on her account, Guava died on May 24 from a "sudden illness", as translated from English. The influencer created mukbang videos, in which she would eat makeup products, including lipstick, blush, face masks and cotton pads. Mukbang is a popular online trend, especially in South Korea, where a person films themselves eating a large amount of food while interacting with an audience. The post announcing the tragic news reads: "Although this trip came suddenly, Shuishui held on to every difficult moment just like she has always been - hard-working, serious, and shining. "Thank you to everyone who has liked, left a message and laughed with her, and thank you for your love and support. "She really keeps it in her heart and cherishes it very much. "Guava Shuishui simply continues to glow in a different place. When we meet again one day, she should be unboxing angels' exclusive makeup for eating broadcasts over." More to follow... For the latest news on this story, keep checking back at The U.S. Sun, your go-to destination for the best celebrity news, sports news, real-life stories, jaw-dropping pictures, and must-see videos . Most read in The US Sun Like us on Facebook at
